Yeasts of the Cryptococcus species complex are the causative agent of cryptococcosis, especially in human immunodeficiency virus (HIV) positive individuals. Cerebral or disseminated cryptococcosis has a very high mortality rate worldwide, including in Thailand. Additionally, an increasing rate of antifungal drug resistant cryptococcal isolates has been reported in several neighboring countries, complicating therapeutic approaches. To understand the situation of this infection in Thailand, we retrospectively investigated the molecular epidemiology and antifungal drug resistance in a collection of 74 clinical, 52 environmental and two veterinary isolates using the URA5-RFLP for typing and the EUCAST guideline for susceptibility testing. Where no EUCAST breakpoints (AMB and 5FC) were available, CLSI epidemiologic cutoff values were used for interpretation. Cryptococcal molecular type diversity showed most isolates were C. grubii, molecular type VNI. One clinical isolate was C. deuterogattii (mol. type VGII) and another C. grubii (mol. type VNII). One strain from environment was classified as C. grubii (mol. type VNII). No resistant strains were detected in this retrospective study for either of the antimycotics tested; however, monitoring of the epidemiology of Cryptococcus species in infected patients in Thailand needs to be continued to detect emergence of resistance.
Introduction
Cryptococcosis is a life-threatening disease, ranging as the second most prevalent systemic fungal infection worldwide and currently the most prevalent systemic infection in immunocompromised hosts, representing more than 70% of cases. 1 The causative agent of this invasive mycosis is due to basidiomycetous encapsulated yeasts of the Cryptococcus gattii/C. neoformans species complex. 2 In developing countries C. neoformans is one of the major opportunist infecting patients with human immunodeficiency virus (HIV)/AIDS and other immunocompromised individuals; C. gattii is mostly diagnosed in immunocompetent host from tropical and subtropical regions. [1] [2] [3] [4] [5] Annually, more than 625,000 deaths and around 1 million new infections have been reported with the increasing trend correlated to the HIV/AIDS burden in sub-Saharan Africa and Southeast Asia, including Thailand. 6, 7 For clinical treatment of cryptococcosis the combination of amphotericine B (AMB) and 5-flucytosine (5FC) follow by prolonged fluconazole (FLC) during the maintenance period are indicated. 8 In contrast, high-dose (1,200 mg/day) of FLC monotherapy is often used in poor healthcare settings, regardless of species of Cryptococcus or molecular type. 1, 9 Moreover, there are the evidence reports that the in vitro susceptibility profile of causative Cryptococcus isolates are correlated with their species. [10] [11] [12] [13] [14] [15] The average MICs towards azoles, especially FLC, are highest in C. deuterogattii. 10, 12, 14, 16, 17 Since Cryptococcus species are not part of the normal flora of man, exogenous routes of infections cause by basidiospores inhalation was proposed. Cryptococcal yeasts can also be isolated from the Thai environment. 18 In Thai patients, C. gattii and C. bacillisporus have been found as the major causes of cryptococcosis before the AIDS era, but the prevalence has changed in recent years. C. grubii has now become the most common causative agent of cryptococcal meningitis. 19 However, the genetic diversity of Thai isolates is expected to be more diverse since C. neoformans and C. gattii-group (VG) strains have also been isolated before in Thailand. 20 Moreover, an increasing rate of drug resistant Cryptococci has been reported from several countries in Asia neighboring Thailand, especially in HIV/AIDS populations. [21] [22] [23] This indicates the necessity to understand the current epidemiology of cryptococci down to the molecular level including the determination of the respective susceptibility profiles.
To better understand the epidemiology of cryptococci in Thailand we molecularly characterized clinical, environmental, and veterinary Cryptococcus spp. isolates from Thailand using URA5-RFLP technique and determined their susceptibility pattern based on the EUCAST technique.
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Materials and methods
Nomenclature
Recently, the nomenclature for the Cryptococcus species complex has been redefined based on a number of molecular typing techniques such as multilocus enzyme typing, amplified fragment length polymorphism, polymerase chain reaction (PCR) fingerprinting using M13 and random amplification of polymorphic DNA. 26 This newly proposed nomenclature has been adopted in this manuscript where possible, and is therefore shortly outlined. Seven haploid genotypes have been defined: C. grubii, consisting of the major genotype (AFLP1/VNI, serotype A) and the two minor genotypes AFLP1A/VNII and AFLP1B/VNII. For C. neoformans, only one genotype (AFLP2/VNIV, serotype D) was associated. What was previously known as C. gattii was split into five major genotypes, raised to species: C. gattii sensu stricto (AFLP4/VGI, serotype B), C. bacillisporus (AFLP5/VGIII, serotype C), C. deuterogattii (AFLP6/VGII), C. tetragattii (AFLP7/VGIV), and C. decagattii (AFLP10/VGIV). Where they are not further discriminated, these are here referred to as the 'C. gattii group.' Moreover, several interspecies and intervarietal hybrids are also described in the literature. 26 
Strains
The 128 Cryptococcus isolated from human, environment, and veterinary specimens were selected from the culture collections in Mycology research unit, Faculty of Medicine, Chulalongkorn University (Table 1) . Only the first strain per patient for clinical isolates, per sampling area for environmental and per animal for veterinary isolates was used. All of them were initially confirmed by their morphology and biochemical tests using India-ink preparation, urease test, and phenoloxidase production test. 20 After the strains were recovered from −80
• C stock, all of them were cultured on Sabouraud dextrose agar (SDA) (Becton Dickinson, USA.) at 37
• C and the genus confirmed by MALDI-TOF MS (MALDI Biotyper, Bruker Daltonics, Bremen, Germany). The sources of culture collection isolates were as follows: Clinical strains from human specimen were isolated from cerebrospinal fluid and blood samples of AIDS patients in routine laboratory of King Chulalongkorn Memorial Hospital over a 10-year period (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . Veterinary isolates were obtained from nasal cavity of cats diagnosed with feline immunodeficiency virus (FIV) infection from Faculty of Veterinary Science, Chulalongkorn University (2008). Environmental isolates were derived from pigeon droppings in Bangkok during the years 2002-2005 using a method described previously. 27 Briefly, droppings were suspended in 0.85% sterile normal saline, vigorously vortexed, and the debris allowed settling. The supernatant was diluted and spread on SDA supplemented with 50 μg/ml chloramphenicol, incubated at 37
• C overnight, and inspected for yeast colonies the following day. 
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Antifungal susceptibility testing
The MICs for all isolates were determined by modified method based on the EUCAST guidelines. 24, 25 Briefly, the yeast cells were diluted (1:20 dilution of 0.5 McFarland standard cell density) and tested with AMB (Discovery fine chemicals, Bournemouth, UK), FLC (Discovery fine chemicals) and 5FC (Sigma-Aldrich) at the concentration range of 0.0312-16 μg/ml, 0.125-64 μg/ml, and 0.125-64 μg/ml, respectively. A complete synthetic medium, RPMI-1640 with 0.03% glutamine and supplemented with glucose to a final concentration of 20 g/L (2%) was used as the test medium. Cultures of tested strains in the presence of antifungal agents (including drug-free and sterility control): 0.0312-16 μg/ml of AMB, 0.125-64 μg/ml of FLC, and 0.125-64 μg/ml of 5FC were performed at 30 o C. After 48 h incubation, the result was determined spectrophotometrically at 530 nm. All strains were examined in triplicate in parallel with two quality control strains (C. krusei ATCC 6258 and C. parapsilosis ATCC 22019). For the fungicidal agent AMB the minimal inhibitory concentrations (MICs) endpoint was adopted as the lowest concentration of drug that caused a prominent reduction (MIC 90 ) of growth compared with that of a drug-free growth control well. For the fungistatic drugs FLC and 5FC the MIC endpoint was adopted as the lowest drug concentration at which the growth of the isolates was reduced by 50% or more compared with that of the control (MIC 50 ). 24, 25 In the EUCAST Def. 7.1 document only for FLC a break-point was proposed (S ≤ 2 μg/ml, SDD = 4; R > 4 μg/ml). 24, 25 For AMB and 5FC, a formal break-point has not been established yet. Thus, their MICs was interpreted by comparing with epidemiological cut-off values (ECVs) based on CLSI guideline; M27-A3, 2008. The ECVs cut-off value of AMB was 0.5 μg/ml for both C. neoformans and C. deuterogattii, whereas the ECVs cut-off value of 5FC was 8 μg/ml and 16 μg/ml for C. neoformans and for C. deuterogattii, respectively.
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Results
A total of 128 isolates were included into the study, comprising n = 74 (58%) clinical, n = 52 (40%) environmental, and n = 2 (2%) veterinary isolates. All clinical strains were isolated from HIV-positive patients, most (n = 69; 93.24%) from cerebrospinal fluid, only five (6.76%) from blood culture samples. Veterinary isolates were obtained from nasal cavity of cats diagnosed with FIV infection. For environmental isolates, all strains were isolated from pigeon droppings of 21 districts in Bangkok metropolitan area (Table 1) . Although technically possible, commercially available MALDI-TOF systems do not yet allow for precise discrimination between the newly described Cryptococcus species, 26, 30 URA5-RFLP analysis was used to examine the molecular type diversity within our collection. Three molecular types, VNI, VNII, and VGII were found. Mostly, molecular type VNI (C. grubii) was present with the rates of 97.30% (n = 72/74), 98.08% (n = 51/52), and 100% (n = 2/2) among clinical, environmental, and veterinary isolates, respectively. One molecular type VNII (C. grubii) isolate was found among clinical and environmental sources, and one type VGII isolate was found in the clinical set ( Based on EUCAST def 7.1 guideline, all tested isolates were classified as susceptible to FLC (MIC 50 ≤ 2 μg/ml). The MIC values measured towards AMB and 5FC (Table 1) were not higher than the epidemiological cut-off values of AMB (0.5 μg/ml for C. neoformans) and 5FC (8 μg/ml and 16 μg/ml for C. neoformans and C. deuterogattii, respectively), according the CLSI guideline; M27-A3, 2008, ECVs. 26 Similar to the antifungal profile in the Eastern Thailand 18 and in non-Asian countries, 33 no resistant strains against AMB, FLC, or 5FC were detected. However, the increasing trend of FLC resistance was reported from Cambodia 34 and Singapore. 35 Thus, establishing Cryptococcus epidemiology and determination of the respective susceptibility patterns are indicated to monitor potential emergence of antifungal drug resistance in the future.
